Speaker Profile
M.D., Chief Scientific & Medical Officer, Veracyte
Biography
Dr. Phil Febbo is Chief Scientific and Medical Officer at Veracyte, a global cancer diagnostics company where he remains focused on improving cancer outcomes through the discovery, development, and accessibility of innovative, high-quality molecular diagnostics. He held multiple clinical and scientific roles over 15 years in academia at Dana-Farber, Harvard Medical School, the Whitehead Institute for Genome Research, Duke University, and UCSF where he was Professor of Medicine and Urology. After transitioning to industry, he was Chief Medical Officer at Genomic Health (2013-2018) and Illumina (2018-2023). Dr. Febbo served on the boards of Varian Inc. (Director) and the A CMG Foundation and is currently on the boards of the Reagan Udall Foundation for the FDA (Vice-Chair) and ASC Os Conquer Cancer Foundation. He holds a B. A. in Biology from Dartmouth College, an M. D. from UCSF, completed internal medicine residency at the Brigham and Womens Hospital, and medical oncology fellowship at the DFCI.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Catriona Jamieson, UCSD
Opening talk
• Catriona Jamieson, UCSD
PMWC Award Ceremony
• Judy Faulkner, Epic
• Alexis C. Komor, UCSD
What’s Next at Epic?
• Peter DeVault, Epic
RNA Therapeutics Beyond mRNA: siRNA, ASOs, and snRNA
• Chair: Alexis C. Komor, UCSD
• Niren Murthy, UC Berkeley
• Gene Yeo, UCSD
• Reuben Harris, UT Health San Antonio
Small Molecule Therapeutics Targeting Stem Cells
• Chair: Catriona Jamieson, UCSD
• Irving L. Weissman, Stanford
Space-Omics & Stem-Cell Adaptation
• Chair: Catriona Jamieson, UCSD
• Alysson Muotri, UCSD
In Vivo Gene Therapies
• Chair: Gene Yeo, UCSD
• Mark A Kay, Stanford
• David Schaffer, UC Berkeley
Diagnostics, Prognostics, and Patient Stratification
• Chair: Ezra Cohen, Tempus
• Gudrun Stengel, Alida Biosciences
• David Ledbetter, Florida State University
Bioprinting Transplantable Liver: mRNA-Driven Multi-Lineage Differentiation from Autologous iPSCs
• Jiwu Wang, The Scintillon Institute
A New Era in Heart Failure Treatment: Delivering on the Promise of iPSC-Derived Cardiomyocyte Therapy
• Eugene Wang, Help Therapeutics
Closing Talk
• Catriona Jamieson, UCSD
